公开(公告)号：US20240336572A1

公开(公告)日：2024-10-10

申请号：US18626467

申请日：2024-04-04

Applicant: Pfizer Inc.

Inventor： Samit Kumar Bhattacharya ,  Edward Lee Conn ,  David Christopher Ebner ,  Brian Stephen Gerstenberger ,  Chan Woo Huh ,  Daniel Wei-Shung Kung ,  Alan Martin Mathiowetz ,  Jessica Gloria Katherine O'Brien ,  Meihua Mike Tu ,  Kimberly O'Keefe Cameron ,  Dilinie Prasadhini Fernando ,  Kevin James Filipski ,  Esther Cheng Yin Lee ,  Sarah Jane Mear ,  Aaron Christopher Smith

IPC: C07D231/56 ,  A61K31/416

CPC classification number: C07D231/56 ,  A61K31/416

Abstract: The invention relates to substituted indazole propionic acid derivatives, pharmaceutically acceptable salts, tautomers, or pharmaceutically acceptable salts of the tautomers thereof that can activate adenosine 5′-monophosphate-activated protein kinase (AMPK). The invention further relates to pharmaceutical compositions comprising AMPK-activating substituted indazole propionic acid derivatives, pharmaceutically acceptable salts, tautomers, or pharmaceutically acceptable salts of the tautomers thereof and at least one pharmaceutically acceptable excipient, and methods of treating a condition comprising administering AMPK-activating substituted indazole propionic acid derivatives, pharmaceutically acceptable salts, tautomers, or pharmaceutically acceptable salts of the tautomers thereof.

公开(公告)号：US20160016940A1

公开(公告)日：2016-01-21

申请号：US14773954

申请日：2013-09-24

Applicant: PFIZER INC.

Inventor： Samit Kumar Bhattacharya ,  Kimberly O'Keefe Cameron ,  Matthew Scott Dowling ,  David Christopher Ebner ,  David James Edmonds ,  Dilinie Prasadhini Fernando ,  Kevin James Filipski ,  Daniel Wei-Shung Kung ,  Esther Cheng Yin Lee ,  Aaron Christopher Smith ,  Meihua Mike Tu

IPC: C07D405/12 ,  C07D401/12 ,  C07D403/12 ,  C07D401/04

CPC classification number: C07D405/12 ,  A61K31/4439 ,  C07D401/04 ,  C07D401/12 ,  C07D403/12

Abstract: The present invention relates to indole and indazole compounds of Formula (I) that activate 5′ adenosine monophosphate-activated protein kinase (AMPK). The invention also encompasses pharmaceutical compositions containing these compounds and methods for treating or preventing diseases, conditions, or disorders ameliorated by activation of AMPK.

Abstract translation: 本发明涉及活化5'腺苷单磷酸活化蛋白激酶（AMPK）的式（I）的吲哚和吲唑化合物。 本发明还包括含有这些化合物的药物组合物和用于治疗或预防通过AMPK活化改善的疾病，病症或障碍的方法。

公开(公告)号：US09394285B2

公开(公告)日：2016-07-19

申请号：US14773954

申请日：2013-09-24

Applicant: Pfizer Inc.

Inventor： Samit Kumar Bhattacharya ,  Kimberly O'Keefe Cameron ,  Matthew Scott Dowling ,  David Christopher Ebner ,  David James Edmonds ,  Dilinie Prasadhini Fernando ,  Kevin James Filipski ,  Daniel Wei-Shung Kung ,  Esther Cheng Yin Lee ,  Aaron Christopher Smith ,  Meihua Mike Tu

IPC: C07D405/12 ,  C07D403/12 ,  C07D401/04 ,  C07D401/12 ,  A61K31/404 ,  A61K31/4439 ,  A61K31/454 ,  A61K31/496 ,  A61P13/12 ,  A61P3/10

CPC classification number: C07D405/12 ,  A61K31/4439 ,  C07D401/04 ,  C07D401/12 ,  C07D403/12

Abstract: The present invention relates to indole and indazole compounds of Formula (I) that activate 5′ adenosine monophosphate-activated protein kinase (AMPK). The invention also encompasses pharmaceutical compositions containing these compounds and methods for treating or preventing diseases, conditions, or disorders ameliorated by activation of AMPK.

Abstract translation: 本发明涉及活化5'腺苷单磷酸活化蛋白激酶（AMPK）的式（I）的吲哚和吲唑化合物。 本发明还包括含有这些化合物的药物组合物和用于治疗或预防通过AMPK活化改善的疾病，病症或障碍的方法。